DeepMed Research

Cancer Hospital, Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Immunotherapy
Esophageal Cancer
Chemoradiotherapy
Chemotherapy
Nimotuzumab

Interventions: Combination Product: Nimotuzumab with chemoradiotherapy

First Posted Date: 2024-05-13

Last Posted Date: 2024-05-13

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 53

Registration Number: NCT06410651

Locations: 🇨🇳
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer

Phase 2

Not yet recruiting

Conditions: Liver Cancer

Interventions: Drug: chidamide combined with Sintilimab and bevacizumab

First Posted Date: 2024-05-10

Last Posted Date: 2024-05-10

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 48

Registration Number: NCT06408623

Clinical Trial of BT02 in Patients With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: BT02 monoclonal antibody injection

First Posted Date: 2024-05-08

Last Posted Date: 2024-12-27

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 60

Registration Number: NCT06404905

Locations: 🇨🇳
Cancer Institute and Hospital, Beijing, Biejing, China

NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC

Phase 2

Recruiting

Conditions: Nanoliposomal Irinotecan
Oxaliplatin
Advanced Cancer
Pancreatic Adenocarcinoma
Cadonilimab
Capecitabine
First-Line
Drug Use

Interventions: Drug: Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab

First Posted Date: 2024-05-08

Last Posted Date: 2024-12-24

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 30

Registration Number: NCT06405490

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Magnetic Resonance Imaging-guided Adaptive Radiotherapy for Large Brain Metastases

Recruiting

Conditions: Brain Metastases

Interventions: Radiation: magnetic resonance imaging-guided adaptive radiotherapy

First Posted Date: 2024-05-08

Last Posted Date: 2024-05-08

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 20

Registration Number: NCT06405256

Locations: 🇨🇳
Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China

Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer

Phase 2

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Nanoliposomal Irinotecan, Oxaliplatin plus Capecitabine

First Posted Date: 2024-05-08

Last Posted Date: 2024-11-28

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 36

Registration Number: NCT06405139

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients

Phase 2

Active, not recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab

First Posted Date: 2024-05-08

Last Posted Date: 2024-05-08

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 35

Registration Number: NCT06403709

Locations: 🇨🇳
Beijing Chaoyang Sanhuan Cancer Hospital, Beijing, China

Effect of (neo)Adjuvant Therapy on Lipids in Young Breast Cancer Patients

Conditions: Breast Neoplasms
Lipid Profile

First Posted Date: 2024-05-08

Last Posted Date: 2025-02-14

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 600

Registration Number: NCT06405269

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation

Conditions: Breast Carcinoma
BRCA Mutation
Adjuvant Drug Therapy

Interventions: Other: no intervention

First Posted Date: 2024-05-08

Last Posted Date: 2025-02-14

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 600

Registration Number: NCT06405295

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis

Phase 2

Recruiting

Conditions: Hepatocellular Carcinoma
Radiotherapy
Pembrolizumab
Tumor Thrombosis

Interventions: Radiation: Moderate-dose Hypofractionated Intensity-modulated Radiotherapy
Drug: Pembrolizumab

First Posted Date: 2024-04-29

Last Posted Date: 2024-04-29

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 30

Registration Number: NCT06389422

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciecnces and Peking Union Medical College, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy